Furthermore, programmed cell death protein 1/programmed death-ligand 1 (PD-1/PD-L1) pathway inhibitors, such as pembrolizumab and nivolumab, have demonstrated significant efficacy in patients with EBV+, high microsatellite instability (MSI-H) or a high tumour mutation burden (TMB) [15]. The gene discussed is PDCD1; the disease is neoplasm.